Cargando…

Concordance of Hypermethylated DNA and the Tumor Markers CA 15-3, CEA, and TPA in Serum during Monitoring of Patients with Advanced Breast Cancer

The serological protein tumor markers CA 15-3, CEA, and TPA are frequently used to monitor tumor burden among metastatic breast cancer patients. Breast cancer is associated with global DNA hypomethylation and hypermethylation of some promoter regions. No monitoring study has yet investigated the int...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kristiansen, Søren, Jørgensen, Lars Mønster, Hansen, Morten Høgh, Nielsen, Dorte, Sölétormos, György
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2015
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4538773/ https://www.ncbi.nlm.nih.gov/pubmed/26339655 http://dx.doi.org/10.1155/2015/986024

Ejemplares similares

Detection and monitoring of hypermethylated RASSF1A in serum from patients with metastatic breast cancer
por: Kristiansen, Søren, et al.
Publicado: (2016)

Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases
por: Nicolini, Andrea, et al.
Publicado: (2006)

Evaluation of serum CA15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients.
por: Nicolini, A., et al.
Publicado: (1991)

An individual reference limit of the serum CEA–TPA–CA 15-3 tumor marker panel in the surveillance of asymptomatic women following surgery for primary breast cancer
por: Nicolini, Andrea, et al.
Publicado: (2018)

Performance of seven criteria to assess CA125 increments among ovarian cancer patients monitored during first-line chemotherapy and the post-therapy follow-up period
por: Abu Hassan, Suher O, et al.
Publicado: (2017)

Prognostic value of monitoring tumour markers CA 15-3 and CEA during fulvestrant treatment
por: Bartsch, Rupert, et al.
Publicado: (2006)

Serum CEA and CA 15-3 as prognostic factors in primary breast cancer
por: Ebeling, F G, et al.
Publicado: (2002)

Combined Evaluation of AFP, CA15-3, CA125, CA19-9, and CEA Tumor Markers in Patients with Hepatitis B and C
por: ASSMAR, Mehdi, et al.
Publicado: (2016)

Improved sensitivity for detection of breast cancer by combination of miR-34a and tumor markers CA 15-3 or CEA
por: Zaleski, Martin, et al.
Publicado: (2018)

Primary Cutaneous Mucinous Carcinoma Monitoring: A Role for CA15.3 and CEA?
por: Ginguay, Antonin, et al.
Publicado: (2022)

Diagnostic impact of CEA and CA 15-3 on chemotherapy monitoring of breast cancer patients
por: Hasan, Diya
Publicado: (2022)

Lung tumour markers in oncology practice: a study of TPA and CA125
por: Buccheri, G, et al.
Publicado: (2002)

Menstrual Cycle Dependent Variability for Serum Tumor Markers CEA, AFP, CA 19-9, CA 125 and CA 15-3 in Healthy Women
por: Erbağci, Ayşe Binnur, et al.
Publicado: (1999)

Association of Preoperative Serum Levels of CEA and CA15-3 with Molecular Subtypes of Breast Cancer
por: Zhao, Wenjing, et al.
Publicado: (2021)

Nipple Discharge of CA15-3, CA125, CEA and TSGF as a New Biomarker Panel for Breast Cancer
por: Wang, Gangping, et al.
Publicado: (2014)

Diagnostic Utility of Combined CEA, CA15-3 and CA125 Biomarkers and Cytomorphology in Suspicious and Malignant Serosal Fluid
por: Rahemi, Zahra, et al.
Publicado: (2021)

FTO, PIK3CB serve as potential markers to complement CEA and CA15-3 for the diagnosis of breast cancer
por: Mi, Jintao, et al.
Publicado: (2023)

Clinical utility of tumour marker velocity of cancer antigen 15–3 (CA 15–3) and carcinoembryonic antigen (CEA) in breast cancer surveillance
por: Hing, J.X., et al.
Publicado: (2020)

Serum CA19‐9, CA‐125 and CEA as tumor markers for mucinous ovarian tumors
por: Lertkhachonsuk, Arb‐aroon, et al.
Publicado: (2020)

Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer
por: Shao, Yingbo, et al.
Publicado: (2015)

Use of CEA and CA15-3 to Predict Axillary Lymph Node Metastasis in Patients with Breast Cancer
por: Wu, San-Gang, et al.
Publicado: (2016)

Tumour marker antigen CA125 in pancreatic cancer: a comparison with CA19-9 and CEA.
por: Haglund, C.
Publicado: (1986)

Nomograms for Predicting the Prognostic Value of Pre-Therapeutic CA15-3 and CEA Serum Levels in TNBC Patients
por: Dai, Danian, et al.
Publicado: (2016)

Combined detection of CA15-3, CEA, and SF in serum and tissue of canine mammary gland tumor patients
por: Fan, Yuying, et al.
Publicado: (2021)

CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA.
por: Haglund, C., et al.
Publicado: (1994)

The prognostic role of variations in tumour markers (CEA, CA15.3) in patients with metastatic breast cancer treated with CDK4/6 inhibitors
por: Sottotetti, Federico, et al.
Publicado: (2022)

Cancer Antigens (CEA and CA 19-9) as Markers of Advanced Stage of Colorectal Carcinoma
por: Vukobrat-Bijedic, Zora, et al.
Publicado: (2013)

Structure and density of silicon carbide to 1.5 TPa and implications for extrasolar planets
por: Kim, D., et al.
Publicado: (2022)

Carbon Nanopowder-Based Stochastic Sensor for Ultrasensitive Assay of CA 15-3, CEA and HER2 in Whole Blood
por: Stefan-van Staden, Raluca-Ioana, et al.
Publicado: (2022)

Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy
por: Tuxen, M K, et al.
Publicado: (2001)

Preoperative serum levels of CEA and CA 242 in colorectal cancer.
por: Carpelan-Holmström, M., et al.
Publicado: (1995)

The Clinical Significance of CEA, CA19–9, and CA125 in Management of Appendiceal Adenocarcinoma
por: Yousef, Abdelrahman, et al.
Publicado: (2023)

tPA or not tPA? Lysis therapy in the setting of COVID‐19 and ECMO
por: Cromartie, Anjelica, et al.
Publicado: (2022)

Assessment of tumor markers CA 19-9, CEA, CA 125, and CA 242 for the early diagnosis and prognosis prediction of gallbladder cancer
por: Sinha, Seema Rani, et al.
Publicado: (2022)

The use of tumour markers CEA, CA-195 and CA-242 in evaluating the response to chemotherapy in patients with advanced colorectal cancer.
por: Ward, U., et al.
Publicado: (1993)

Thioredoxin 1 as a serum marker for breast cancer and its use in combination with CEA or CA15-3 for improving the sensitivity of breast cancer diagnoses
por: Park, Byung-Joon, et al.
Publicado: (2014)

Comparison of a new tumour marker CA 242 with CA 19-9, CA 50 and carcinoembryonic antigen (CEA) in digestive tract diseases.
por: Kuusela, P., et al.
Publicado: (1991)

Different Levels of CEA, CA153 and CA125 in Milk and Benign and Malignant Nipple Discharge
por: Zhao, Song, et al.
Publicado: (2016)

Prognostic significance of preoperative serum CA125, CA19-9 and CEA in gastric carcinoma
por: Wang, Wei, et al.
Publicado: (2016)

Diagnostic and Prognostic Value of CEA and CA19-9 in Colorectal Cancer
por: Lakemeyer, Leilani, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_n6d3nu12aee81rg00bm5nic4vd